A Phase Ib/II Study of the CD123-targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax And/or Azacitidine for Patients with CD123-positive Acute Myeloid Leukemia.
JOURNAL OF CLINICAL ONCOLOGY（2020）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要